Based on the results of the TACTI-002 trial, the FDA granted a fast-track designation to eftilagimod alpha in combination with pembrolizumab as a frontline treatment for patients with stage IIIB/IV NSCLC with a PD-L1 TPS score of at least 1%. Here, CD274 is linked to non-small cell lung carcinoma.